Search results
Results From The WOW.Com Content Network
This study was a retrospective, case-control study that compared smoking habits of 684 individuals with bronchogenic carcinoma to those without the condition. [12] The survey included questions about smoking: starting age, 20 year tobacco consumption, brands used; as well as inquires about exposure to hazardous agents in the workplace, alcohol use, and causes of death for family members.
According to the Nurses' Health Study, the risk of large cell lung carcinoma increases with a previous history of tobacco smoking, with a previous smoking duration of 30 to 40 years giving a relative risk of approximately 2.3 compared to never-smokers, and a duration of more than 40 years giving a relative risk of approximately 3.6. [8]
Lung squamous-cell carcinoma is the second most common histologic type of lung cancer after adenocarcinoma, reaching 22.6% of all lung cancer cases as of 2012. [11] The relative incidence of the former has been steadily decreasing in favor of the latter due to the decreasing smoking rates in the last few years. [9]
Lung cancer is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 resulting in 1.8 million deaths. [3] Lung cancer is rare in those younger than 40; the average age at diagnosis is 70 years, and the average age at death 72. [2] Incidence and outcomes vary widely across the world, depending on patterns of tobacco use.
Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. [1] It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis.
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. [1] [2] [3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma.
Results from large randomized studies have recently prompted a large number of professional organizations and governmental agencies in the U.S. to now recommend lung cancer screening in select populations. The 3 main types of lung cancer screening are low-dose, computerized tomographic (LDCT) screening, chest x-rays, and sputum cytology tests. [4]